anurajms/meta_analysis huggingface dataset:
MESH terms:
Preoperative ripening of the cervix before operative hysteroscopy
1. *Cervical Ripening; 2. *Hysteroscopy [adverse effects]; 3. Cervix Uteri [*drug effects, injuries]; 4. Dilatation [*methods]; 5. Dinoprostone [administration & dosage]; 6. Laminaria; 7. Misoprostol [administration & dosage]; 8. Oxytocics [administration & dosage]; 9. Preoperative Care [*methods]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Add‐back therapy with GnRH analogues for uterine fibroids
1. *Quality of Life; 2. Antineoplastic Agents, Hormonal [adverse effects, therapeutic use]; 3. Bone Density [*drug effects]; 4. Bone Density Conservation Agents [adverse effects, therapeutic use]; 5. Drug Therapy, Combination [methods]; 6. Estriol [adverse effects, therapeutic use]; 7. Gonadotropin‐Releasing Hormone [*analogs & derivatives]; 8. Isoflavones [adverse effects, therapeutic use]; 9. Leiomyoma [*drug therapy]; 10. Medroxyprogesterone [adverse effects, therapeutic use]; 11. Norpregnenes [adverse effects, therapeutic use]; 12. Raloxifene Hydrochloride [adverse effects, therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Uterine Hemorrhage [chemically induced, drug therapy]; 15. Uterine Neoplasms [*drug therapy];
MESH terms:
Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
1. *Protein Denaturation; 2. Collagen [*chemistry, *therapeutic use]; 3. Electric Stimulation Therapy [*methods]; 4. Randomized Controlled Trials as Topic; 5. Urinary Catheterization; 6. Urinary Incontinence, Stress [*therapy];
MESH terms:
Hormone therapy for preventing cardiovascular disease in post‐menopausal women
1. Cardiovascular Diseases [mortality, *prevention & control]; 2. Cause of Death; 3. Estrogen Replacement Therapy [adverse effects, methods]; 4. Hormone Replacement Therapy [adverse effects, *methods]; 5. Postmenopause; 6. Primary Prevention; 7. Secondary Prevention; 8. Stroke [chemically induced]; 9. Venous Thromboembolism [chemically induced];
MESH terms:
Nitric oxide donors for cervical ripening in first‐trimester surgical abortion
1. *Abortifacient Agents, Nonsteroidal [adverse effects]; 2. *Nitric Oxide Donors [adverse effects]; 3. *Oxytocics [adverse effects]; 4. Abortion, Induced [*methods]; 5. Cervical Ripening [*drug effects, physiology]; 6. Pregnancy Trimester, First; 7. Prostaglandins; 8. Randomized Controlled Trials as Topic;
MESH terms:
Conservative management for postprostatectomy urinary incontinence
1. Biofeedback, Psychology; 2. Electric Stimulation Therapy [methods]; 3. Erectile Dysfunction [rehabilitation]; 4. Exercise Therapy [methods]; 5. Magnetic Field Therapy [methods]; 6. Pelvic Floor; 7. Prostatectomy [*adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Urinary Incontinence [etiology, *therapy];
MESH terms:
Imiquimod for anogenital warts in non‐immunocompromised adults
1. *Immunocompetence; 2. Aminoquinolines [adverse effects, *therapeutic use]; 3. Anus Diseases [*drug therapy, virology]; 4. Genital Diseases, Female [*drug therapy, virology]; 5. Genital Diseases, Male [*drug therapy, virology]; 6. Imiquimod; 7. Interferon Inducers [adverse effects, *therapeutic use]; 8. Keratolytic Agents [therapeutic use]; 9. Podophyllin [therapeutic use]; 10. Podophyllotoxin [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Recurrence; 13. Self Administration; 14. Warts [*drug therapy];
MESH terms:
Minimally invasive surgical techniques versus open myomectomy for uterine fibroids
1. Fever [etiology]; 2. Hysteroscopy [adverse effects, *methods]; 3. Laparoscopy [adverse effects, *methods]; 4. Laparotomy [adverse effects, *methods]; 5. Leiomyoma [*surgery]; 6. Pain Measurement; 7. Pain, Postoperative; 8. Randomized Controlled Trials as Topic; 9. Uterine Myomectomy [adverse effects, *methods]; 10. Uterine Neoplasms [*surgery];
MESH terms:
Types of indwelling urethral catheters for short‐term catheterisation in hospitalised adults
1. Alloys; 2. Anti‐Infective Agents, Urinary [administration & dosage]; 3. Catheter‐Related Infections [etiology, *prevention & control]; 4. Catheters, Indwelling [*adverse effects]; 5. Minocycline [administration & dosage]; 6. Nitrofurazone [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Rifampin [administration & dosage]; 9. Silver; 10. Urinary Catheterization [adverse effects, *instrumentation]; 11. Urinary Tract Infections [etiology, *prevention & control]; 12. Urination Disorders [therapy];
MESH terms:
Non‐surgical interventions for the management of chronic pelvic pain
1. Amines [therapeutic use]; 2. Amitriptyline [therapeutic use]; 3. Analgesics [adverse effects, therapeutic use]; 4. Chronic Pain [*therapy]; 5. Clonidine [adverse effects, analogs & derivatives, therapeutic use]; 6. Contraceptive Agents, Female [adverse effects, therapeutic use]; 7. Cyclohexanecarboxylic Acids [therapeutic use]; 8. Gabapentin; 9. Goserelin [therapeutic use]; 10. Medroxyprogesterone Acetate [adverse effects, therapeutic use]; 11. Pain Measurement; 12. Pelvic Pain [*therapy]; 13. Psychotherapy; 14. Randomized Controlled Trials as Topic; 15. gamma‐Aminobutyric Acid [therapeutic use];
MESH terms:
Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding
1. Danazol [therapeutic use]; 2. Dilatation and Curettage; 3. Dysmenorrhea [prevention & control]; 4. Endometrium [*drug effects, *surgery]; 5. Gonadotropin-Releasing Hormone [agonists]; 6. Menorrhagia [*surgery]; 7. Preoperative Care [*methods]; 8. Progestins [therapeutic use]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Aromatase inhibitors for uterine fibroids
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Aromatase Inhibitors [adverse effects, *therapeutic use]; 3. Hot Flashes [chemically induced]; 4. Leiomyoma [*drug therapy]; 5. Letrozole; 6. Nitriles [adverse effects, therapeutic use]; 7. Triazoles [adverse effects, therapeutic use]; 8. Triptorelin Pamoate [therapeutic use]; 9. Uterine Neoplasms [*drug therapy];
MESH terms:
Paracervical local anaesthesia for cervical dilatation and uterine intervention
1. Anesthesia, Local [adverse effects, *methods]; 2. Anesthesia, Obstetrical [adverse effects, *methods]; 3. Anesthetics, Local [administration & dosage, adverse effects]; 4. Biopsy [adverse effects]; 5. Dilatation and Curettage [*adverse effects]; 6. Endometrium [pathology]; 7. Hysteroscopy [adverse effects]; 8. Nerve Block [*methods]; 9. Pain [*prevention & control]; 10. Pain, Postoperative [prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Uterus [*surgery];
MESH terms:
Prophylactic antibiotics for transcervical intrauterine procedures
1. *Antibiotic Prophylaxis; 2. Cervix Uteri [surgery]; 3. Dilatation and Curettage [adverse effects]; 4. Gynecologic Surgical Procedures [adverse effects, *methods];
MESH terms:
Anti‐TNF‐α treatment for pelvic pain associated with endometriosis
1. Anti‐Inflammatory Agents [*therapeutic use]; 2. Antibodies, Monoclonal [*therapeutic use]; 3. Endometriosis [*complications]; 4. Infliximab; 5. Pelvic Pain [*drug therapy]; 6. Premenopause; 7. Randomized Controlled Trials as Topic; 8. Tumor Necrosis Factor‐alpha [*antagonists & inhibitors];
MESH terms:
Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers
1. *Shift Work Schedule; 2. Sleep; 3. Sleep Duration; 4. *Sleep Quality; 5. Sleepiness;
MESH terms:
Splinting for carpal tunnel syndrome
1. *Carpal Tunnel Syndrome [therapy]; 2. Hand; 3. *Occupational Therapy; 4. Quality of Life; 5. Upper Extremity;
MESH terms:
Collective leadership to improve professional practice, healthcare outcomes and staff well‐being
1. Delivery of Health Care; 2. Health Personnel; 3. *Leadership; 4. *Occupational Stress; 5. Professional Practice; 6. Randomized Controlled Trials as Topic;
MESH terms:
Pre‐deployment programmes for building resilience in military and frontline emergency service personnel
1. *Cognitive Behavioral Therapy; 2. *Military Personnel; 3. *Mindfulness; 4. Randomized Controlled Trials as Topic; 5. *Resilience, Psychological; 6. *Stress Disorders, Post-Traumatic [prevention & control];
MESH terms:
Exercise therapy for chronic low back pain
1. Exercise; 2. Exercise Therapy; 3. *Low Back Pain [therapy]; 4. Mind-Body Therapies; 5. *Musculoskeletal Manipulations;
MESH terms:
Interventions to improve return to work in depressed people
1. *Absenteeism; 2. Antidepressive Agents [therapeutic use]; 3. Bias; 4. Cognitive Behavioral Therapy; 5. Depression [*therapy]; 6. Depressive Disorder, Major [*therapy]; 7. Muscle Stretching Exercises; 8. *Occupational Health; 9. Randomized Controlled Trials as Topic; 10. Return to Work [*psychology]; 11. Sick Leave; 12. Work Performance;
MESH terms:
Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff
1. Betacoronavirus; 2. Body Fluids; 3. Computer Simulation; 4. *Coronavirus Infections [epidemiology, prevention & control, transmission]; 5. COVID-19; 6. Gloves, Protective; 7. Health Personnel; 8. *Hemorrhagic Fever, Ebola [prevention & control, transmission]; 9. *Infection Control [methods]; 10. Infectious Disease Transmission, Patient-to-Professional [*prevention & control]; 11. Odds Ratio; 12. *Pandemics [prevention & control]; 13. *Personal Protective Equipment; 14. *Pneumonia, Viral [epidemiology, prevention & control, transmission]; 15. Protective Clothing; 16. Respiratory Protective Devices; 17. SARS-CoV-2; 18. *Severe Acute Respiratory Syndrome [prevention & control, transmission];
MESH terms:
Workplace interventions for increasing standing or walking for decreasing musculoskeletal symptoms in sedentary workers
1. *Sedentary Behavior; 2. *Standing Position; 3. Ergonomics [methods]; 4. Musculoskeletal Diseases [*prevention & control]; 5. Occupational Diseases [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Walking [*physiology]; 8. Workplace [*statistics & numerical data];
MESH terms:
Work‐break schedules for preventing musculoskeletal symptoms and disorders in healthy workers
1. *Health Personnel; 2. *Personnel Staffing and Scheduling; 3. Ergonomics; 4. Health Workforce; 5. Musculoskeletal Diseases [*prevention & control]; 6. Occupational Diseases [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Workplace;
MESH terms:
Incentives for smoking cessation
1. *Motivation; 2. Behavior Therapy; 3. Health Facilities; 4. Randomized Controlled Trials as Topic; 5. Reward; 6. Smoking Cessation [*methods, *psychology]; 7. Smoking Prevention; 8. Workplace;
MESH terms:
Ergonomic interventions for preventing work‐related musculoskeletal disorders of the upper limb and neck among office workers
1. *Neck; 2. *Upper Extremity; 3. Computer Peripherals; 4. Equipment Design; 5. Ergonomics [*methods]; 6. Musculoskeletal Diseases [*prevention & control]; 7. Occupational Diseases [*prevention & control]; 8. Orthotic Devices; 9. Patient Education as Topic [methods]; 10. Randomized Controlled Trials as Topic; 11. Rest;
MESH terms:
Ergonomic interventions for preventing musculoskeletal disorders in dental care practitioners
1. Dental Equipment; 2. Dental Instruments; 3. *Dentists; 4. Equipment Design; 5. Ergonomics [*methods]; 6. Exercise; 7. Musculoskeletal Diseases [*prevention & control]; 8. Occupational Diseases [*prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Self Report [statistics & numerical data];
MESH terms:
Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff
1. *Hazardous Substances [analysis, urine]; 2. *Nursing Staff, Hospital; 3. *Pharmacists; 4. *Pharmacy Technicians; 5. Antineoplastic Agents [analysis, urine]; 6. Chemical Safety [*instrumentation, *methods]; 7. Cyclophosphamide [analysis, urine]; 8. Deoxycytidine [analogs & derivatives, analysis, urine]; 9. Endocrine Disruptors [analysis, urine]; 10. Fluorouracil [analysis, urine]; 11. Ifosfamide [analysis, urine]; 12. Observational Studies as Topic; 13. Occupational Exposure [*prevention & control];
MESH terms:
Workplace lighting for improving alertness and mood in daytime workers
1. *Affect; 2. *Awareness; 3. *Workplace; 4. Controlled Before‐After Studies; 5. Lighting [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Multidisciplinary biopsychosocial rehabilitation for subacute low back pain
1. Acute Pain [psychology, *rehabilitation]; 2. Combined Modality Therapy; 3. Low Back Pain [psychology, *rehabilitation]; 4. Pain Clinics; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic; 7. Recovery of Function; 8. Return to Work [statistics & numerical data]; 9. Sick Leave [statistics & numerical data];
MESH terms:
Influenza vaccination for healthcare workers who care for people aged 60 or older living in long‐term care institutions
1. *Health Personnel; 2. Homes for the Aged; 3. Infectious Disease Transmission, Professional‐to‐Patient [*prevention & control]; 4. Influenza Vaccines [*administration & dosage]; 5. Influenza, Human [prevention & control, *transmission]; 6. Randomized Controlled Trials as Topic; 7. Vaccines, Inactivated [administration & dosage];
MESH terms:
Rehabilitation following carpal tunnel release
1. Carpal Tunnel Syndrome [*rehabilitation, *surgery]; 2. Outcome Assessment, Health Care; 3. Postoperative Care [*methods]; 4. Randomized Controlled Trials as Topic; 5. Rehabilitation [methods];
MESH terms:
Organisational interventions for improving wellbeing and reducing work‐related stress in teachers
1. *Faculty; 2. *Schools; 3. Anxiety [prevention & control]; 4. Career Mobility; 5. Depression [prevention & control]; 6. Mentors; 7. Motivation; 8. Occupational Diseases [*prevention & control, psychology]; 9. Randomized Controlled Trials as Topic; 10. Stress, Psychological [*prevention & control];
MESH terms:
Exercises for mechanical neck disorders
1. *Physical Therapy Modalities; 2. Acute Pain [therapy]; 3. Chronic Pain [therapy]; 4. Headache [etiology, therapy]; 5. Manipulation, Chiropractic [*methods]; 6. Neck; 7. Neck Pain [etiology, *therapy]; 8. Pain Management [methods]; 9. Radiculopathy [*therapy]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Multidisciplinary biopsychosocial rehabilitation for chronic low back pain
1. Back Pain [psychology, *rehabilitation]; 2. Chronic Pain [psychology, *rehabilitation]; 3. Occupational Therapy [methods]; 4. Pain Measurement; 5. Psychotherapy; 6. Randomized Controlled Trials as Topic; 7. Social Support; 8. Work;
MESH terms:
Interventions for preventing the spread of infestation in close contacts of people with scabies
1. Scabies [*prevention & control, *transmission];
MESH terms:
Non‐pharmacological interventions for preventing venous insufficiency in a standing worker population
1. *Air Travel; 2. *Posture; 3. *Stockings, Compression; 4. Chronic Disease; 5. Cross‐Over Studies; 6. Occupational Diseases [*prevention & control]; 7. Prospective Studies; 8. Venous Insufficiency [*prevention & control];
MESH terms:
Supported employment for adults with severe mental illness
1. Employment, Supported [*psychology, statistics & numerical data]; 2. Mental Disorders [*rehabilitation]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Physical conditioning as part of a return to work strategy to reduce sickness absence for workers with back pain
1. *Exercise Therapy; 2. *Return to Work; 3. Acute Pain [rehabilitation]; 4. Back Pain [*rehabilitation]; 5. Chronic Pain [rehabilitation]; 6. Cognitive Behavioral Therapy; 7. Neck Pain [*rehabilitation]; 8. Occupational Therapy; 9. Pain Measurement; 10. Physical Fitness; 11. Randomized Controlled Trials as Topic; 12. Sick Leave; 13. Treatment Outcome;
MESH terms:
Therapeutic ultrasound for carpal tunnel syndrome
1. Carpal Tunnel Syndrome [*therapy]; 2. Combined Modality Therapy [methods]; 3. Randomized Controlled Trials as Topic [standards]; 4. Time Factors; 5. Treatment Outcome; 6. Ultrasonic Therapy [*methods];
MESH terms:
Training healthcare providers to respond to intimate partner violence against women
1. Bias; 2. Dentists [education]; 3. Health Personnel [*education]; 4. *Intimate Partner Violence; 5. Medical Staff [education]; 6. Midwifery [education]; 7. Nursing Staff [education]; 8. Psychology [education]; 9. Randomized Controlled Trials as Topic; 10. Social Workers [education]; 11. Students, Health Occupations;
MESH terms:
Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation
1. Anxiety [psychology, therapy]; 2. *Atrial Fibrillation [therapy]; 3. *Coronary Disease; 4. Depression [psychology, therapy]; 5. *Heart Failure [therapy]; 6. Psychosocial Intervention; 7. Quality of Life;
MESH terms:
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease
1. Bias; 2. *Cardiovascular Diseases [prevention & control]; 3. *Cell Phone; 4. *Medication Adherence; 5. Myocardial Infarction [prevention & control]; 6. *Randomized Controlled Trials as Topic; 7. Reminder Systems; 8. *Secondary Prevention [methods]; 9. Stroke [prevention & control]; 10. *Text Messaging;
MESH terms:
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery
1. *Adrenal Cortex Hormones [adverse effects, therapeutic use]; 2. Atrial Fibrillation [mortality, prevention & control]; 3. Bias; 4. *Cardiac Surgical Procedures [adverse effects, mortality]; 5. *Cardiopulmonary Bypass [adverse effects, mortality]; 6. Cause of Death; 7. Coronary Artery Disease [mortality, surgery]; 8. Heart Valve Diseases [mortality, surgery]; 9. Length of Stay; 10. *Postoperative Complications [mortality, prevention & control]; 11. *Randomized Controlled Trials as Topic; 12. Respiration, Artificial [adverse effects, statistics & numerical data];
MESH terms:
Exercise‐based cardiac rehabilitation for adults with heart failure
1. *Cardiac Rehabilitation [methods]; 2. Exercise; 3. Exercise Therapy; 4. *Heart Failure; 5. Quality of Life;
MESH terms:
Home‐based versus centre‐based cardiac rehabilitation
1. *Cardiac Rehabilitation; 2. *Heart Failure; 3. Hospitals; 4. *Myocardial Infarction; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Effects of interventions targeting the systemic inflammatory response to cardiac surgery on clinical outcomes in adults
1. *Cardiac Surgical Procedures [adverse effects]; 2. Inflammation; 3. *Interleukin-6; 4. Interleukin-8; 5. Systemic Inflammatory Response Syndrome;
MESH terms:
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage
1. Anticoagulants [therapeutic use]; 2. *Antifibrinolytic Agents [therapeutic use]; 3. Cerebral Hemorrhage [drug therapy]; 4. Fibrinolytic Agents [therapeutic use]; 5. *Hemostatics [therapeutic use]; 6. *Stroke [drug therapy];
MESH terms:
Cerebrolysin for acute ischaemic stroke
1. Amino Acids [adverse effects]; 2. *Ischemic Stroke [chemically induced, drug therapy]; 3. Peptides; 4. *Stroke [chemically induced, drug therapy]; 5. Swine;
MESH terms:
Pravastatin for lowering lipids
1. Atorvastatin; 2. *Cardiovascular Diseases; 3. Cholesterol, HDL; 4. Cholesterol, LDL; 5. *Drug-Related Side Effects and Adverse Reactions; 6. Fluvastatin; 7. *Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects]; 8. Pravastatin [adverse effects]; 9. Rosuvastatin Calcium;
MESH terms:
First‐line diuretics versus other classes of antihypertensive drugs for hypertension
1. Adrenergic beta-Antagonists [adverse effects]; 2. Angiotensin Receptor Antagonists [adverse effects]; 3. Angiotensin-Converting Enzyme Inhibitors [adverse effects]; 4. Antihypertensive Agents [adverse effects]; 5. Calcium Channel Blockers [adverse effects]; 6. *Coronary Disease; 7. *Diabetes Mellitus, Type 2 [drug therapy]; 8. Diuretics [adverse effects]; 9. *Heart Failure [drug therapy]; 10. *Hypertension [chemically induced]; 11. *Stroke [drug therapy]; 12. Thiazides [adverse effects];
MESH terms:
Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency
1. Body Weight; 2. Evidence Gaps; 3. Exercise; 4. Veins; 5. *Venous Insufficiency [therapy];
MESH terms:
Risk of thromboembolism in patients with COVID‐19 who are using hormonal contraception
1. Contraceptive Agents; 2. *COVID-19; 3. Estrogens [adverse effects]; 4. Hormonal Contraception; 5. Pandemics; 6. *Thrombosis; 7. *Venous Thromboembolism [chemically induced, epidemiology];
MESH terms:
Family presence during resuscitation
1. *Anxiety; 2. Anxiety Disorders; 3. Critical Care; 4. Pilot Projects; 5. Randomized Controlled Trials as Topic; 6. *Resuscitation;
MESH terms:
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
1. Anticoagulants [adverse effects]; 2. Antithrombins [adverse effects]; 3. Dabigatran [adverse effects]; 4. Factor Xa Inhibitors [adverse effects]; 5. Hemorrhage [chemically induced]; 6. Neoplasm Recurrence, Local [drug therapy]; 7. *Pulmonary Embolism [drug therapy, prevention & control]; 8. Rivaroxaban [adverse effects]; 9. *Venous Thromboembolism [prevention & control]; 10. *Venous Thrombosis [complications];
MESH terms:
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
1. *Anticoagulants [therapeutic use]; 2. *Antithrombins [therapeutic use]; 3. *Factor Xa Inhibitors [therapeutic use]; 4. Hemorrhage [chemically induced]; 5. Neoplasm Recurrence, Local [drug therapy]; 6. *Pulmonary Embolism [drug therapy, prevention & control]; 7. *Venous Thromboembolism [prevention & control];
MESH terms:
General versus loco‐regional anesthesia for endovascular aortic aneurysm repair
1. *Anesthesia, Conduction [adverse effects]; 2. Anesthesia, General [adverse effects]; 3. *Anesthetics, General; 4. *Aortic Aneurysm, Abdominal [surgery]; 5. *Endovascular Procedures [adverse effects, methods]; 6. Prospective Studies; 7. Quality of Life;
MESH terms:
Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation
1. Anti-Arrhythmia Agents [adverse effects]; 2. *Atrial Fibrillation [drug therapy, surgery]; 3. *Catheter Ablation [adverse effects]; 4. *Heart Failure [drug therapy]; 5. *Myocardial Infarction;
MESH terms:
Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis
1. Aprotinin; 2. Blood Transfusion; 3. Deamino Arginine Vasopressin [therapeutic use]; 4. Fibrin Tissue Adhesive; 5. Hemorrhage [etiology, prevention & control]; 6. Network Meta-Analysis; 7. *Tranexamic Acid [therapeutic use];
MESH terms:
Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis
1. Angioplasty [adverse effects]; 2. Arteries; 3. Constriction, Pathologic [therapy]; 4. *Hemorrhagic Stroke [complications]; 5. *Ischemic Attack, Transient [complications]; 6. *Ischemic Stroke [complications]; 7. *Stroke [etiology, prevention & control];
MESH terms:
Antithrombotic treatment after stroke due to intracerebral haemorrhage
1. Anticoagulants [adverse effects]; 2. *Atrial Fibrillation; 3. Cerebral Hemorrhage; 4. Fibrinolytic Agents [adverse effects]; 5. Platelet Aggregation Inhibitors [adverse effects]; 6. *Stroke [drug therapy];
MESH terms:
Intravenous immunoglobulin for the treatment of Kawasaki disease
1. *Acute Coronary Syndrome; 2. Aspirin [adverse effects]; 3. Fever [drug therapy, etiology]; 4. Immunoglobulins, Intravenous [adverse effects]; 5. Inflammation; 6. *Mucocutaneous Lymph Node Syndrome [drug therapy]; 7. Prednisolone [therapeutic use];
MESH terms:
Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular surgical procedures
1. *Endovascular Procedures [adverse effects, methods]; 2. Ischemia; 3. *Ischemic Preconditioning [methods]; 4. Myocardial Infarction [etiology]; 5. Stroke [etiology]; 6. *Vascular Surgical Procedures [adverse effects, methods];
MESH terms:
Totally percutaneous versus surgical cut‐down femoral artery access for elective bifurcated abdominal endovascular aneurysm repair
1. *Aortic Aneurysm, Abdominal [surgery]; 2. *Blood Vessel Prosthesis Implantation; 3. Endovascular Aneurysm Repair; 4. *Endovascular Procedures [adverse effects, methods]; 5. Femoral Artery [surgery]; 6. Groin [surgery]; 7. Hematoma; 8. Randomized Controlled Trials as Topic; 9. *Wound Infection;
MESH terms:
Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack
1. *Insulin Resistance; 2. *Ischemic Attack, Transient [prevention & control]; 3. *Myocardial Infarction; 4. PPAR gamma [agonists, therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. *Stroke;
MESH terms:
Balneotherapy for chronic venous insufficiency
1. *Balneology; 2. Edema; 3. *Leg Ulcer; 4. Pain; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. *Venous Insufficiency [therapy];
MESH terms:
High versus low blood pressure targets for cardiac surgery while on cardiopulmonary bypass
1. Acute Kidney Injury [epidemiology]; 2. *Cardiac Surgical Procedures [adverse effects]; 3. *Cardiopulmonary Bypass [adverse effects]; 4. Hemorrhagic Stroke; 5. Hypertension; 6. Hypotension; 7. Randomized Controlled Trials as Topic;
MESH terms:
Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
1. Anticoagulants [therapeutic use]; 2. *Bariatric Surgery [adverse effects, methods]; 3. Hemorrhage [etiology]; 4. Heparin [therapeutic use]; 5. *Pulmonary Embolism [etiology, prevention & control]; 6. Randomized Controlled Trials as Topic; 7. *Venous Thromboembolism [drug therapy, prevention & control];
MESH terms:
Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding
1. *Cardiac Surgical Procedures [adverse effects]; 2. Erythrocyte Transfusion; 3. *Hemorrhage [etiology, therapy];
MESH terms:
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
1. Blood Pressure; 2. *Cardiovascular Diseases; 3. *Hypertension [complications]; 4. *Hypotension; 5. *Myocardial Infarction; 6. *Stroke [complications];
MESH terms:
Pharmaceutical interventions for emotionalism after stroke
1. Antidepressive Agents [therapeutic use]; 2. Crying [psychology]; 3. Emotions; 4. Pharmaceutical Preparations; 5. Randomized Controlled Trials as Topic; 6. *Stroke [drug therapy, psychology];
MESH terms:
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
1. *Antifibrinolytic Agents [therapeutic use]; 2. *Brain Ischemia; 3. *Hydrocephalus; 4. Persistent Vegetative State [drug therapy]; 5. *Subarachnoid Hemorrhage [drug therapy];
MESH terms:
Interventions for perceptual disorders following stroke
1. Activities of Daily Living; 2. *Perceptual Disorders [etiology, rehabilitation]; 3. Randomized Controlled Trials as Topic; 4. *Stroke [complications]; 5. *Stroke Rehabilitation; 6. Vision Disorders [rehabilitation];
MESH terms:
Endovascular therapy versus medical treatment for spontaneous isolated dissection of the superior mesenteric artery
1. Abdominal Pain [etiology, therapy]; 2. *Aortic Dissection [surgery]; 3. *Endovascular Procedures [methods]; 4. Mesenteric Artery, Superior [surgery]; 5. Tomography, X-Ray Computed; 6. Treatment Outcome;
MESH terms:
Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism
1. Acute Disease; 2. Anticoagulants [therapeutic use]; 3. Hemorrhage [etiology]; 4. *Pulmonary Embolism [drug therapy, etiology]; 5. Thrombolytic Therapy [methods]; 6. *Tissue Plasminogen Activator [therapeutic use];
MESH terms:
Action observation for upper limb rehabilitation after stroke
1. Activities of Daily Living; 2. Physical Therapy Modalities; 3. Randomized Controlled Trials as Topic; 4. *Stroke [complications]; 5. *Stroke Rehabilitation; 6. Upper Extremity;
MESH terms:
Patch angioplasty versus primary closure for carotid endarterectomy
1. *Angioplasty [adverse effects, methods]; 2. *Endarterectomy, Carotid [adverse effects, methods]; 3. Randomized Controlled Trials as Topic; 4. Stroke [epidemiology];
MESH terms:
Antiplatelet agents for the treatment of deep venous thrombosis
1. Anticoagulants [adverse effects]; 2. Hemorrhage [chemically induced]; 3. Platelet Aggregation Inhibitors [adverse effects]; 4. *Pulmonary Embolism [drug therapy, etiology]; 5. *Venous Thromboembolism; 6. *Venous Thrombosis [drug therapy];
MESH terms:
Type of anaesthesia for acute ischaemic stroke endovascular treatment
1. Anesthesia, General; 2. *Brain Ischemia [surgery]; 3. Intracranial Hemorrhages; 4. *Ischemic Stroke; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Retrospective Studies; 8. *Stroke [surgery];
MESH terms:
Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
1. Catheter-Related Infections [epidemiology]; 2. *Central Venous Catheters; 3. Hemorrhage [chemically induced]; 4. *Heparin [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. *Saline Solution [adverse effects]; 7. Sepsis; 8. Thrombocytopenia [chemically induced];
MESH terms:
Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia
1. Amputation, Surgical; 2. *Bone Marrow; 3. Ischemia [etiology, surgery]; 4. *Peripheral Arterial Disease [complications, surgery]; 5. Randomized Controlled Trials as Topic; 6. Transplantation, Autologous [adverse effects];
MESH terms:
Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting)
1. Anesthesia, General; 2. Carotid Arteries [surgery]; 3. Electroencephalography; 4. *Endarterectomy, Carotid [adverse effects, methods]; 5. Randomized Controlled Trials as Topic; 6. *Stroke [epidemiology];
MESH terms:
Corticosteroids for the treatment of Kawasaki disease in children
1. Adrenal Cortex Hormones [adverse effects]; 2. *Coronary Artery Disease; 3. Fever [drug therapy]; 4. Immunoglobulins, Intravenous [adverse effects]; 5. Length of Stay; 6. *Mucocutaneous Lymph Node Syndrome [drug therapy];
MESH terms:
Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis
1. Angioplasty [adverse effects, methods]; 2. *Ischemic Attack, Transient [etiology]; 3. Stents [adverse effects]; 4. *Stroke [complications]; 5. *Vertebrobasilar Insufficiency [complications, therapy];
MESH terms:
Outpatient versus inpatient treatment for acute pulmonary embolism
1. Acute Disease; 2. Hemorrhage [epidemiology, therapy]; 3. Hospitalization; 4. Inpatients; 5. *Outpatients; 6. *Pulmonary Embolism [therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Endovascular versus conventional open surgical repair for thoracoabdominal aortic aneurysms
1. *Aortic Aneurysm, Thoracic [surgery]; 2. Arteries; 3. *Endovascular Procedures;
MESH terms:
Occupational therapy for cognitive impairment in stroke patients
1. Activities of Daily Living; 2. *Cognitive Dysfunction [complications]; 3. *Occupational Therapy [methods]; 4. Randomized Controlled Trials as Topic; 5. *Stroke [complications, psychology]; 6. *Stroke Rehabilitation;
MESH terms:
Angioplasty versus stenting for subclavian artery stenosis
1. Angioplasty; 2. Constriction, Pathologic [therapy]; 3. Stents; 4. *Subclavian Steal Syndrome [therapy]; 5. Systematic Reviews as Topic;
MESH terms:
Ultrafiltration for acute heart failure
1. *Heart Failure [therapy]; 2. Renal Replacement Therapy; 3. Respiration, Artificial; 4. *Ultrafiltration;
MESH terms:
Oral antiplatelet therapy for acute ischaemic stroke
1. Aspirin [adverse effects]; 2. *Brain Ischemia [drug therapy]; 3. *Ischemic Stroke; 4. Platelet Aggregation Inhibitors [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. *Stroke [drug therapy];
MESH terms:
Calcium channel blockers versus other classes of drugs for hypertension
1. Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; 2. Antihypertensive Agents [adverse effects]; 3. Calcium Channel Blockers [adverse effects]; 4. *Hypertension [drug therapy]; 5. *Pharmaceutical Preparations;
MESH terms:
Percutaneous thrombectomy or ultrasound‐accelerated thrombolysis for initial management of acute limb ischaemia
1. *Endovascular Procedures; 2. Fibrinolytic Agents [therapeutic use]; 3. *Ischemia [drug therapy, therapy]; 4. Thrombectomy; 5. Thrombolytic Therapy [adverse effects];
MESH terms:
Propionyl‐L‐carnitine for intermittent claudication
1. Ankle Brachial Index; 2. Carnitine [therapeutic use]; 3. *Intermittent Claudication [drug therapy]; 4. *Peripheral Arterial Disease [complications]; 5. Randomized Controlled Trials as Topic; 6. Walking;
MESH terms:
Psychological and pharmacological interventions for depression in patients with coronary artery disease
1. *Coronary Artery Disease [complications]; 2. *Depression [therapy]; 3. Escitalopram; 4. Psychotherapy; 5. Quality of Life;
MESH terms:
Endovascular versus open surgical repair for complicated chronic Type B aortic dissection
1. Aorta, Thoracic; 2. *Aortic Dissection [surgery]; 3. Ischemia;
MESH terms:
Injection sclerotherapy for varicose veins
1. Sclerotherapy [adverse effects]; 2. *Varicose Ulcer; 3. *Varicose Veins [therapy]; 4. Veins; 5. *Venous Insufficiency;
MESH terms:
Environmental enrichment for stroke and other non‐progressive brain injury
1. *Brain Injuries; 2. Quality of Life; 3. Randomized Controlled Trials as Topic; 4. Recovery of Function; 5. *Stroke [therapy]; 6. *Stroke Rehabilitation;
MESH terms:
Renal denervation for resistant hypertension
1. *Antihypertensive Agents [therapeutic use]; 2. Blood Pressure; 3. Denervation; 4. *Hypertension [drug therapy]; 5. Kidney [physiology, surgery];
MESH terms:
Interventions for altering blood pressure in people with acute subarachnoid haemorrhage
1. Activities of Daily Living; 2. Blood Pressure; 3. *Brain Ischemia; 4. Quality of Life; 5. *Subarachnoid Hemorrhage;
MESH terms:
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
1. Anxiety; 2. Anxiety Disorders; 3. Fluoxetine [adverse effects]; 4. *Selective Serotonin Reuptake Inhibitors [adverse effects]; 5. *Stroke [drug therapy];
MESH terms:
Exercise‐based cardiac rehabilitation for coronary heart disease
1. *Cardiac Rehabilitation; 2. *Coronary Artery Disease; 3. Exercise; 4. Exercise Therapy; 5. *Myocardial Infarction;
MESH terms:
Beta‐blockers in patients without heart failure after myocardial infarction
1. Cause of Death; 2. *Heart Failure [drug therapy]; 3. *Myocardial Infarction [complications, drug therapy]; 4. Quality of Life; 5. Stroke Volume; 6. Ventricular Function, Left;
MESH terms:
Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis
1. *Cardiovascular Diseases; 2. *Dipeptidyl-Peptidase IV Inhibitors [adverse effects]; 3. Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; 4. Glucagon-Like Peptide 1; 5. Glucose; 6. Network Meta-Analysis; 7. Sodium; 8. *Sodium-Glucose Transporter 2 Inhibitors [adverse effects]; 9. *Symporters;
MESH terms:
Anticoagulants for acute ischaemic stroke
1. Activities of Daily Living; 2. Anticoagulants [adverse effects]; 3. *Brain Ischemia [drug therapy]; 4. Heparin [adverse effects]; 5. *Ischemic Stroke; 6. *Stroke [drug therapy, prevention & control]; 7. Systematic Reviews as Topic;
MESH terms:
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
1. Anticoagulants [adverse effects]; 2. Arrhythmias, Cardiac; 3. *Catheter Ablation; 4. Heparin [adverse effects]; 5. *Quality of Life;
MESH terms:
Local versus general anaesthesia for carotid endarterectomy
1. Anesthesia, General [adverse effects]; 2. Anesthesia, Local [adverse effects]; 3. *Carotid Stenosis [surgery]; 4. *Endarterectomy, Carotid [adverse effects]; 5. *Stroke [epidemiology, etiology, prevention & control];
MESH terms:
Ultrasound guidance for arterial (other than femoral) catheterisation in adults
1. *Arteries; 2. *Catheterization; 3. Ultrasonography;
MESH terms:
Treatment for telangiectasias and reticular veins
1. Pruritus [drug therapy]; 2. Sclerotherapy; 3. *Telangiectasis [therapy]; 4. *Veins;
MESH terms:
Pharmacotherapy for hypertension‐induced left ventricular hypertrophy
1. Antihypertensive Agents [therapeutic use]; 2. *Cardiovascular Diseases; 3. *Hypertension [complications, drug therapy]; 4. Hypertrophy, Left Ventricular [drug therapy, etiology]; 5. Methyldopa;
MESH terms:
Hybrid repair versus conventional open repair for aortic arch dissection
1. Aortic Aneurysm, Thoracic [classification, *surgery]; 2. Combined Modality Therapy; 3. Randomized Controlled Trials as Topic; 4. Vascular Grafting;
MESH terms:
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts
1. Arteriovenous Shunt, Surgical [*adverse effects, *methods]; 2. Chemotherapy, Adjuvant; 3. Fish Oils [therapeutic use]; 4. Graft Occlusion, Vascular [prevention & control]; 5. Kidney Failure, Chronic [*therapy]; 6. Platelet Aggregation Inhibitors [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Renal Dialysis [methods]; 9. Ticlopidine [therapeutic use]; 10. Vascular Access Devices; 11. Vascular Patency [*drug effects];
MESH terms:
Stem cell therapy for dilated cardiomyopathy
1. Arrhythmias, Cardiac [epidemiology]; 2. Bias; 3. Cardiomyopathy, Dilated [mortality, *therapy]; 4. Cause of Death; 5. Granulocyte Colony-Stimulating Factor [therapeutic use]; 6. Placebos [therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Severity of Illness Index; 10. *Stem Cell Transplantation [adverse effects, mortality]; 11. Walk Test; 12. Watchful Waiting;
MESH terms:
Graduated compression stockings for the initial treatment of varicose veins in people without venous ulceration 
1. Bias; 2. Edema [diagnosis]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. *Stockings, Compression; 6. Treatment Outcome; 7. Varicose Ulcer; 8. Varicose Veins [*therapy];
MESH terms:
Cilostazol for intermittent claudication
1. Bias; 2. Cilostazol [*therapeutic use]; 3. Intermittent Claudication [*drug therapy, etiology]; 4. Myocardial Infarction [prevention & control]; 5. Pentoxifylline [therapeutic use]; 6. Peripheral Vascular Diseases [complications, drug therapy]; 7. Placebos [therapeutic use]; 8. Platelet Aggregation Inhibitors [adverse effects, *therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Stroke [prevention & control]; 11. Tetrazoles [adverse effects, *therapeutic use]; 12. Walking;
MESH terms:
Retroperitoneal versus transperitoneal approach for elective open abdominal aortic aneurysm repair
1. Aortic Aneurysm, Abdominal [*surgery]; 2. Bias; 3. Blood Loss, Surgical [statistics & numerical data]; 4. Elective Surgical Procedures [adverse effects, *methods, mortality]; 5. Hematoma [epidemiology]; 6. Length of Stay; 7. Operative Time; 8. Pain, Postoperative [epidemiology]; 9. Peritoneum; 10. Postoperative Complications [epidemiology]; 11. Randomized Controlled Trials as Topic; 12. Retroperitoneal Space;
MESH terms:
Endovascular thrombectomy and intra‐arterial interventions for acute ischaemic stroke
1. Bias; 2. Cause of Death; 3. Fibrinolytic Agents [*administration & dosage]; 4. Infarction, Middle Cerebral Artery [therapy]; 5. Intracranial Hemorrhages [epidemiology, etiology]; 6. Ischemic Stroke [drug therapy, *therapy]; 7. Mechanical Thrombolysis [*methods]; 8. Randomized Controlled Trials as Topic; 9. Thrombolytic Therapy [*methods]; 10. Urokinase-Type Plasminogen Activator [administration & dosage];
MESH terms:
Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Bias; 3. Contusions [chemically induced, pathology, *prevention & control]; 4. Hematoma [chemically induced, pathology]; 5. Heparin, Low-Molecular-Weight [*administration & dosage, adverse effects]; 6. Injections, Subcutaneous [adverse effects, *methods]; 7. Pain Measurement [methods]; 8. Pain, Procedural [etiology, *prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Hybrid repair versus conventional open repair for thoracic aortic arch aneurysms
1. Aortic Aneurysm, Thoracic [*surgery]; 2. *Negative Results;
MESH terms:
Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
1. Adrenergic beta-Antagonists [*therapeutic use]; 2. Angiotensin Receptor Antagonists [*therapeutic use]; 3. Angiotensin-Converting Enzyme Inhibitors [*therapeutic use]; 4. Chronic Disease; 5. Heart Failure [*drug therapy, mortality]; 6. Hospitalization; 7. Mineralocorticoid Receptor Antagonists [*therapeutic use]; 8. Neprilysin [antagonists & inhibitors]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Renin-Angiotensin System [*drug effects]; 12. *Stroke Volume;
MESH terms:
Anticoagulation versus placebo for heart failure in sinus rhythm
1. Administration, Oral; 2. Anticoagulants [adverse effects, *therapeutic use]; 3. Aspirin [therapeutic use]; 4. Cardiomyopathy, Dilated [*complications]; 5. Chronic Disease; 6. Heart Failure [*complications, mortality]; 7. Heart Rate; 8. Hemorrhage [chemically induced]; 9. Placebo Effect; 10. Placebos [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Rivaroxaban [therapeutic use]; 13. Stroke [prevention & control]; 14. Thromboembolism [etiology, mortality, *prevention & control]; 15. Warfarin [adverse effects, therapeutic use];
MESH terms:
Vasodilators for primary Raynaud's phenomenon
1. Administration, Oral; 2. Administration, Topical; 3. Adrenergic alpha-Antagonists [administration & dosage]; 4. Angiotensin-Converting Enzyme Inhibitors [administration & dosage, adverse effects]; 5. Bias; 6. Phosphodiesterase Inhibitors [administration & dosage]; 7. Placebos [therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Raynaud Disease [*drug therapy]; 11. Selective Serotonin Reuptake Inhibitors [therapeutic use]; 12. Thromboxane-A Synthase [antagonists & inhibitors]; 13. Vasodilator Agents [*administration & dosage];
MESH terms:
Fludrocortisone for orthostatic hypotension
1. Bias; 2. Diabetes Mellitus; 3. Domperidone [therapeutic use]; 4. Dysautonomia, Familial [complications]; 5. Fludrocortisone [*therapeutic use]; 6. Hypotension, Orthostatic [*drug therapy]; 7. Observational Studies as Topic; 8. Parkinson Disease [complications]; 9. Pyridostigmine Bromide [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Exercise‐based cardiac rehabilitation for adults after heart valve surgery
1. Aortic Valve [surgery]; 2. Cardiac Rehabilitation [*methods]; 3. Exercise; 4. *Exercise Tolerance; 5. Heart Valve Prosthesis Implantation [mortality, *rehabilitation]; 6. Mitral Valve [surgery]; 7. Physical Conditioning, Human [*methods]; 8. Randomized Controlled Trials as Topic; 9. Resistance Training; 10. Return to Work; 11. Time Factors;
MESH terms:
Endoluminal interventions versus surgical interventions for stenosis in vein grafts following infrainguinal bypass
1. Aneurysm [surgery]; 2. Angioplasty [*methods]; 3. Constriction, Pathologic [therapy]; 4. Graft Occlusion, Vascular [*therapy]; 5. Intermittent Claudication [surgery]; 6. Ischemia [surgery]; 7. Leg [*blood supply]; 8. Peripheral Arterial Disease [*surgery]; 9. Saphenous Vein [transplantation]; 10. Vascular Patency;
MESH terms:
Thrombolytic therapy for pulmonary embolism
1. Acute Disease; 2. Bias; 3. Cause of Death; 4. Fibrinolytic Agents [adverse effects, *therapeutic use]; 5. Hemorrhage [chemically induced, epidemiology]; 6. Heparin [adverse effects, *therapeutic use]; 7. Pulmonary Embolism [*drug therapy, mortality]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Thrombolytic Therapy [adverse effects, *methods];
MESH terms:
Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
1. Bias; 2. Blood Pressure; 3. Cardiovascular Diseases [*prevention & control]; 4. *Cell Phone; 5. Cholesterol, LDL [blood]; 6. *Medication Adherence; 7. Primary Prevention [*methods]; 8. Randomized Controlled Trials as Topic; 9. *Text Messaging;
MESH terms:
Antibiotics for secondary prevention of coronary heart disease
1. Anti-Bacterial Agents [*adverse effects, therapeutic use]; 2. Cardiovascular Diseases [mortality]; 3. Cause of Death; 4. Coronary Disease [mortality, *prevention & control]; 5. Death, Sudden, Cardiac [epidemiology]; 6. Macrolides [adverse effects, therapeutic use]; 7. Myocardial Infarction [epidemiology]; 8. Quinolones [adverse effects, therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Secondary Prevention [*methods]; 11. Stroke [epidemiology];
MESH terms:
Surgical and radiological interventions for treating symptomatic extracranial cervical artery dissection
1. Anticoagulants [therapeutic use]; 2. Arteries; 3. *Ischemic Attack, Transient [complications]; 4. *Stroke [drug therapy, etiology];
MESH terms:
Long‐term effects of weight‐reducing drugs in people with hypertension
1. Anti-Obesity Agents [*adverse effects, therapeutic use]; 2. Appetite Depressants [*adverse effects, therapeutic use]; 3. Bias; 4. Blood Pressure [drug effects]; 5. Body Weight [drug effects]; 6. Bupropion [adverse effects, therapeutic use]; 7. Diet, Reducing; 8. Drug Combinations; 9. Fructose [adverse effects, analogs & derivatives, therapeutic use]; 10. Hypertension [*drug therapy, mortality]; 11. Lactones [adverse effects, therapeutic use]; 12. Naltrexone [adverse effects, therapeutic use]; 13. Orlistat [adverse effects, therapeutic use]; 14. Phentermine [adverse effects, therapeutic use]; 15. Piperidines [adverse effects, therapeutic use]; 16. Pyrazoles [adverse effects, therapeutic use]; 17. Randomized Controlled Trials as Topic; 18. Safety-Based Drug Withdrawals; 19. Time; 20. Topiramate [adverse effects, therapeutic use];
MESH terms:
Blood pressure targets in adults with hypertension
1. Antihypertensive Agents [*therapeutic use]; 2. Bias; 3. Blood Pressure [*physiology]; 4. Cardiovascular Diseases [mortality]; 5. Cause of Death; 6. Confidence Intervals; 7. Diastole [physiology]; 8. Guidelines as Topic; 9. Heart Failure [prevention & control]; 10. Hypertension [*drug therapy, mortality]; 11. Kidney Failure, Chronic [mortality]; 12. Myocardial Infarction [prevention & control]; 13. Numbers Needed To Treat; 14. Randomized Controlled Trials as Topic; 15. Reference Values; 16. Stroke [epidemiology];
MESH terms:
Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection)
1. Chagas Cardiomyopathy [drug therapy]; 2. Chagas Disease [*drug therapy]; 3. Chronic Disease; 4. Nifurtimox [adverse effects, *therapeutic use]; 5. Nitroimidazoles [adverse effects, *therapeutic use]; 6. Parasitemia [drug therapy]; 7. Placebos [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Trypanocidal Agents [adverse effects, *therapeutic use]; 10. Trypanosoma cruzi;
MESH terms:
Angioplasty versus stenting for iliac artery lesions
1. Angioplasty [adverse effects, *methods]; 2. Arterial Occlusive Diseases [*therapy]; 3. Constriction, Pathologic [therapy]; 4. *Iliac Artery; 5. Randomized Controlled Trials as Topic; 6. Retreatment; 7. *Stents; 8. Treatment Outcome;
MESH terms:
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
1. Cardiac Output, Low [*drug therapy, etiology, mortality]; 2. Cardiotonic Agents [*therapeutic use]; 3. Cause of Death; 4. Dobutamine [therapeutic use]; 5. Enoximone [therapeutic use]; 6. Epinephrine [therapeutic use]; 7. Hydrazones [therapeutic use]; 8. Myocardial Infarction [*complications, mortality]; 9. Nitric Oxide [therapeutic use]; 10. Placebos [therapeutic use]; 11. Pyridazines [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Shock, Cardiogenic [*drug therapy, etiology, mortality]; 14. Simendan [therapeutic use]; 15. Vasodilator Agents [*therapeutic use];